MIV 711

Drug Profile

MIV 711

Alternative Names: MIV-711

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Medivir AB
  • Class Antineoplastics; Osteoporosis therapies; Small molecules
  • Mechanism of Action Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • No development reported Bone metastases; Osteoporosis

Most Recent Events

  • 01 Feb 2017 An independent Data Monitoring Committee recommends continuation of the MIV-711-201 phase IIa study in Osteoarthritis after evaluation of safety data from 200 patients
  • 08 Dec 2016 An independent Data Monitoring Committee recommends continuation of the MIV-711-201 phase IIa study in Osteoarthritis
  • 27 Oct 2016 Medivir completes enrolment in its phase IIb trial for Osteoarthritis in Bulgaria, Georgia, Germany, Moldova, Romania and United Kingdom (NCT02705625)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top